News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

454 Life Sciences and Roche NimbleGen, Inc Announce Collaboration with Eli Lilly and Company (LLY) and SeqWright to Sequence Genomic Regions Associated with Psychiatric Disease


7/30/2009 9:01:33 AM

BRANFORD, Conn.--(BUSINESS WIRE)--454 Life Sciences, a Roche company, and Roche NimbleGen, both units of Roche Applied Science, have announced a collaboration with Eli Lilly and Company and SeqWright, a world-wide leader in custom genomic and molecular biology services. The goal of this collaboration is to use leading edge genomic technologies to identify genetic variants possibly associated with various psychiatric diseases. SeqWright will utilize NimbleGen Sequence Capture technology to selectively enrich approximately 40 megabases of the human genome, which will then be comprehensively sequenced using 454 Life Sciences’ Genome Sequencer FLX System.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES